Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 20.6% in March

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 583,900 shares, an increase of 20.6% from the March 15th total of 484,000 shares. Based on an average daily volume of 174,600 shares, the days-to-cover ratio is presently 3.3 days.

Oramed Pharmaceuticals Stock Down 4.0 %

Shares of NASDAQ:ORMP traded down $0.10 during trading on Monday, hitting $2.42. The stock had a trading volume of 152,599 shares, compared to its average volume of 172,240. Oramed Pharmaceuticals has a 12-month low of $1.67 and a 12-month high of $5.25. The stock has a market capitalization of $98.06 million, a price-to-earnings ratio of 17.29 and a beta of 1.81. The stock has a 50-day simple moving average of $2.95 and a two-hundred day simple moving average of $2.48.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last announced its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.04. As a group, sell-side analysts forecast that Oramed Pharmaceuticals will post -0.26 earnings per share for the current year.

Institutional Trading of Oramed Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ORMP. Point72 Hong Kong Ltd grew its holdings in shares of Oramed Pharmaceuticals by 113.5% during the 1st quarter. Point72 Hong Kong Ltd now owns 4,552 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 2,420 shares during the period. UBS Group AG raised its position in Oramed Pharmaceuticals by 84.9% in the 3rd quarter. UBS Group AG now owns 8,415 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 3,864 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Oramed Pharmaceuticals by 27,382.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,344 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 9,310 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Oramed Pharmaceuticals during the 3rd quarter worth about $26,000. Finally, Invesco Ltd. acquired a new stake in shares of Oramed Pharmaceuticals during the 3rd quarter worth about $26,000. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.